# Immunoregulatory Therapy for 2019-nCoV

> **NCT04268537** · PHASE2 · UNKNOWN · sponsor: **Southeast University, China** · enrollment: 120 (estimated)

## Conditions studied

- 2019 nCoV, PD-1

## Interventions

- **DRUG:** PD-1 blocking antibody+standard treatment
- **DRUG:** Thymosin+standard treatment
- **OTHER:** standard treatment

## Key facts

- **NCT ID:** NCT04268537
- **Lead sponsor:** Southeast University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-10
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-10-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04268537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04268537, "Immunoregulatory Therapy for 2019-nCoV". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04268537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*